There are currently 826 clinical trials in Indianapolis, Indiana looking for participants to engage in research studies. Trials are conducted at various facilities, including Indiana University, Indiana University Melvin and Bren Simon Cancer Center, Riley Hospital for Children and Indiana University Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Assessment of CCM in HF With Higher Ejection Fraction
NCT05064709
Recruiting
The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Franciscan Health Indianapolis, Indianapolis, Indiana +1 locations
Conditions: Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction, Diastolic Heart Failure
Register for Updates
Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency
NCT06452316
Recruiting
This study will enroll subjects with qualifying limbal stem cell deficiency (LSCD). All subjects will receive CSB-001 investigational drug in either one or both study eyes. The study is comprised of two identical phases (Dosing Phase I and II) of test article dosing separated by a 31- to 40-day period, the Dosing Holiday, where no test article is administered. Dosing Phase II is followed by an observational, noninterventional phase (Observation Phase).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Francis Price Jr, MD, Indianapolis, Indiana
Conditions: Limbal Stem Cell Deficiency
Register for Updates
Emicizumab in Patients With Acquired Hemophilia A
NCT05345197
Recruiting
This is a phase II multicenter open-label, single-arm prospective study to evaluate the efficacy of prophylactic emicizumab administered on a scheduled basis to prevent bleeds in patients with acquired hemophilia A (AHA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Indiana Hemophilia and Thrombosis Center, Inc., Indianapolis, Indiana
Conditions: Acquired Hemophilia A
Register for Updates
CONVERGE Post-Approval Study (PAS)
NCT05393180
Recruiting
The primary objective of CONVERGE PAS is to evaluate clinical outcomes (peri-procedural and long-term) in a cohort of patients treated during commercial use of the EPi-Sense® Guided Coagulation System or EPi-Sense ST™ Coagulation System to treat symptomatic long-standing persistent atrial fibrillation (AF) patients who are refractory or intolerant to at least one Class I and/or III AAD.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/02/2025
Locations: Ascension St. Vincent, Indianapolis, Indiana
Conditions: Chronic Atrial Fibrillation
Register for Updates
Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial
NCT05478304
Recruiting
This trial is a prospective, randomized, multicenter, multinational, blinded, superiority trial. The objective of this trial is to evaluate the effectiveness of left atrial appendage exclusion (LAAE) for the prevention of ischemic stroke or systemic arterial embolism in subjects undergoing cardiac surgery who have risk factors for atrial fibrillation and ischemic stroke.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Franciscan, Indianapolis, Indiana
Conditions: Ischemic Stroke, Systemic Embolism
Register for Updates
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
NCT05198674
Recruiting
The purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in subjects treated with renal denervation. Additionally, long-term follow-up data will also be collected from eligible subjects previously treated in the SPYRAL PIVOTAL-SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED studies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: St. Vincents Hospital, Indianapolis, Indiana
Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
Register for Updates
Mechanisms Underlying Impaired Diabetic Wound Healing
NCT00777712
Recruiting
The overall aim of this research is to utilize wound derived inflammatory cells from diabetic versus non diabetic human chronic wounds to understand mechanisms that are responsible for disregulated inflammation in individuals with diabetes. Biology of normal (peripheral blood derived cells) versus wound derived cells will also be studied.
Gender:
ALL
Ages:
Between 21 years and 80 years
Trial Updated:
06/02/2025
Locations: Comprehensive Wound Care Centers, Indianapolis, Indiana
Conditions: Non-healing Wounds, Diabetes
Register for Updates
Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection
NCT05219110
Recruiting
The objective of this study is to determine if early high volume intravenous fluid administration (hyperhydration) may be effective in mitigating or preventing complications of shiga toxin-producing E. coli (STEC) infection in children and adolescents when compared with traditional approaches (conservative fluid management).
Gender:
ALL
Ages:
Between 9 months and 21 years
Trial Updated:
06/02/2025
Locations: Indiana University Children's Hospital, Indianapolis, Indiana
Conditions: Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection, Hemolytic-Uremic Syndrome
Register for Updates
Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
NCT06605378
Recruiting
This research study is designed to assess the prevalence of specific antibodies and inflammatory cytokines in adult and pediatric participants with CGD.
Gender:
ALL
Ages:
All
Trial Updated:
05/30/2025
Locations: Home-based telemedicine, Indianapolis, Indiana
Conditions: Chronic Granulomatous Disease (CGD)
Register for Updates
Phase 1 Open-Label Study BL-M17D1 w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
NCT06714617
Recruiting
The objective of this study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of BL-M17D1 in patients with HER2-Expressing or HER2-Mutant Advanced or Metastatic Solid Tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: Indiana University, Indianapolis, Indiana
Conditions: Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer, Unresectable Breast Carcinoma, Her2-Positive, HER2 Gene Mutation, Gastroesophageal-junction Cancer, Non Small Cell Lung Cancer, Endometrial Neoplasms, Peritoneal Cancer, Fallopian Tube Cancer, Ovarian Cancer, Urothelial Carcinoma Bladder, Solid Tumor, Adult, Gastric Cancer
Register for Updates
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
NCT06846515
Recruiting
This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
05/30/2025
Locations: Arthrosi Investigative Site (678), Indianapolis, Indiana
Conditions: Gout, Arthritis, Gouty, Hyperuricemia, Gout Chronic
Register for Updates
An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
NCT06129240
Recruiting
Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 \& 3 PH.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/30/2025
Locations: Vincent Medical Group, Indianapolis, Indiana
Conditions: Pulmonary Hypertension, Interstitial Lung Disease
Register for Updates